Risk factors for fluoroquinolone resistance in Gram-negative bacilli causing healthcare-acquired urinary tract infections.

The Journal of Hospital Infection
P RattanaumpawanE Lautenbach

Abstract

The prevalence of urinary tract infections caused by fluoroquinolone-resistant Gram-negative bacilli (FQ-resistant GNB-UTIs) has been increasing. Previous studies that explored risk factors for FQ resistance have focused only on UTIs caused by Escherichia coli and/or failed to distinguish colonisation from infection. We conducted a case-control study at two medical centres within the University of Pennsylvania Health System to identify risk factors for FQ resistance among healthcare-acquired GNB-UTIs. Subjects with positive urine cultures for GNB and who met Centers for Disease Control and Prevention criteria for healthcare-acquired UTI were eligible. Cases were subjects with FQ-resistant GNB-UTI and controls were subjects with FQ-susceptible GNB-UTI matched to cases by month of isolation and species of infecting organism. In total, 251 cases and 263 controls were included from 1 January 2003 to 31 March 2005. Independent risk factors (adjusted odds ratio; 95% confidence interval) for FQ resistance included male sex (2.03; 1.21-3.39; P=0.007), African-American race (1.80; 1.10-2.94; P=0.020), chronic respiratory disease (2.58; 1.18-5.62; P=0.017), residence in a long term care facility (4.41; 1.79-10.88; P=0.001), hospitalisati...Continue Reading

References

Mar 1, 1984·Antimicrobial Agents and Chemotherapy·N X Chin, H C Neu
Aug 1, 1984·European Journal of Clinical Microbiology·J T Smith
Oct 3, 2001·The Journal of Antimicrobial Chemotherapy·L LeiboviciS D Pitlik
Nov 20, 2002·Archives of Internal Medicine·Ebbing LautenbachBrian L Strom
Feb 27, 2004·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Ebbing LautenbachNeil O Fishman
May 20, 2004·The Annals of Pharmacotherapy·Karla M KillgoreB Joseph Guglielmo
Mar 5, 2005·The American Journal of Medicine·Jeffrey A LinderRandall S Stafford
Sep 22, 2005·The Journal of Antimicrobial Chemotherapy·Hande ArslanUNKNOWN Urinary Tract Infection Study Group
Oct 31, 2006·The American Journal of Medicine·Alana E CohenDarren R Linkin
Jul 11, 2007·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Bernard C CaminsHenry M Blumberg
Feb 26, 2008·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·N GrudeB-E Kristiansen
Feb 26, 2008·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Kazuyoshi ShigeharaMasayoshi Shimamura
Apr 22, 2008·European Urology·A M Jikke BootsmaAstrid Goossens
Sep 24, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·David A TalanUNKNOWN EMERGEncy ID NET Study Group
Oct 1, 2008·The American Journal of Medicine·Luke JohnsonConnie Savor Price
Jul 2, 2009·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Ebbing LautenbachDonald D Stieritz
Jul 9, 2009·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Kathryn J EagyeDavid P Nicolau

❮ Previous
Next ❯

Citations

Jun 19, 2013·Journal of the American Medical Directors Association·Paul J DrinkaDavid A Nace
Aug 16, 2011·The American Journal of Geriatric Pharmacotherapy·S James Matthews, Jason W Lancaster
Jan 30, 2015·The Journal of Antimicrobial Chemotherapy·Pinyo RattanaumpawanUNKNOWN CDC Prevention Epicenters Program
Oct 21, 2011·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Pinyo RattanaumpawanEbbing Lautenbach
Apr 26, 2013·Expert Opinion on Pharmacotherapy·Cédric RafatAlexandre Hertig
Oct 8, 2016·Postgraduate Medicine·Mazen S BaderAnnie A Brooks
Jan 19, 2018·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Kuan-Hsiang Gary HuangOlajumoke Fadugba
Apr 5, 2013·Clinical Microbiology Reviews·Vered SchechnerMitchell J Schwaber
Nov 22, 2017·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Charlesnika T EvansKatie J Suda
Oct 4, 2018·Prostate Cancer and Prostatic Diseases·Wei Phin TanMichael R Abern
Sep 11, 2019·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Bat-Sheva GottesmanMichal Chowers

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Acinetobacter Infections

Acinetobacter infections have become common in hospitalized patients, especially in the intensive care unit setting and are difficult to treat due to their propensity to develop antimicrobial drug resistance. Discover the latest research on Acinetobacter Infections here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.